Search for a command to run...
<bold>Background:</bold> A community airway diagnostics service was created to support access to spirometry and diagnosis in the North-West. This service evaluation aims to describe the patients diagnosed with asthma split by subtype. <bold>Methods:</bold> A retrospective analysis of referrals and reports for patients seen between 11/23-01/24 was conducted. Data included demographics, biomarkers and spirometry results. Patients were categorised into type 2 high (T2H) asthma (raised blood eosinophils (EC)>0.5x10<sup>9</sup>/L, raised FeNO>50ppb or both), and type 2 low (T2L, no raised biomarkers). <bold>Results:</bold> Of the 869 patients reviewed, 23.6% (205) were diagnosed with asthma. Patients with asthma were predominantly female (52.6%) and White (66.0%), with a median age of 55. 57.1% were T2L with no raised biomarkers. 37.6% were T2H, of which 44.1% had raised EC, 35.1% had raised FeNO, and 20.8% had both biomarkers raised. The T2L group had 2.9% more females and a median age 3 years older than the T2H group, but neither were significant at this sample size (p=0.11, p=0.50). There was no significant difference in sex, BMI, FEV1 reversibility or deprivation decile. T2H patients were significantly more likely to be started on inhalers prior to diagnosis (79.2% vs 63.2%, p=0.038). More patients were referred for asthma in the T2H group and more for COPD in the T2L group (p=0.003, p<0.01). Current smoking rate was significantly lower in the T2H group by 18.2% (p=0.004). Intrinsically, the T2H group had significantly higher EOS and FeNO (p<0.001 each). <bold>Conclusion:</bold> A high proportion of patients with confirmed asthma did not have any positive biomarkers. Expert review will continue to be valuable in providing a diagnosis for the T2L group under the new asthma guidelines.